Carl Zeiss Vision International has announced an agreement to acquire Brighten Optix, enhancing its portfolio of myopia management and also integrating specialty contact lenses.
The definitive agreement is to acquire100% of the shares in Brighten Optix, listed on Taipei Exchange.
Brighten Optix is a leading player in the field of orthokeratology (OK) and specialty contact lenses. With this acquisition, ZEISS Vision Care is making a strong addition to its already successful myopia management portfolio.
Brighten Optix products, including myOK, are already widely available in Greater China and across Southeast Asia. Its portfolio of specialty contact lenses will complement ZEISS Vision Care’s existing myopia control offerings.
“We are already proud of our spectacle lens portfolio… we also know that we need to offer even more options…
OK lenses are used to manage progressive myopia in children; a condition which can lead to high myopia and even loss of sight. Brighten Optix offers some of the market’s most advanced products and brands such as myOK.
“Progressive myopia is one of the biggest vision care challenges we see in the world today,” said Sven Hermann, CEO of ZEISS Vision Care and Member of the Executive Board of ZEISS.
“We are already proud of our spectacle lens portfolio, which is clinically proven to significantly slow the progression of myopia. But at the same time, we also know that we need to offer even more options… our future partnership will allow us to meet exactly this need.
“We will broaden our portfolio and enable our customers to protect and improve the vision of many more children”, he said.
Brighten Optix General Manager Richard Wu said the company was “excited to join a leading, worldwide and visionary company like ZEISS”.
“Our business has flourished thanks to pioneering, industry-leading products, and we’re eager to capitalise on this chance to help grow and shape the future of vision care and in particular contact lenses and myopia management.”
The acquisition, which is subject to completion of certain conditions and all applicable regulatory approvals, is expected to close early 2026.
